Altis實驗室

2023年6月26日

Debiopharm創新基金和Benchstrength聯合種子一輪融資支持Altis AI-powered成像平台Altis生物實驗室,計算成像公司加速臨床試驗與人工智能,宣布關閉其600萬美元的種子資金。Benchstrength和Debiopharm創新基金共同參與戰略天使包括道格·福斯特,數字醫療公司的前首席執行官Verana健康,和理查德Gliklich,醫學博士,真實數據公司的創始人兼首席執行官OM1。“這裏程碑Altis證明了加拿大的主導作用在人工智能和臨床研究”“我們是激動與Benchstrength合作和Debiopharm,”巴爾道夫Felix -Lenschen說Altis的聯合創始人兼首席執行官。”這一夥伴關係將幫助我們執行我們的任務,以減少所花費的過多的時間和成本帶來新穎、有效的治療方法,病人的需要。“醫學影像占90%的醫療數據。Altis成立的信念成像臨床資料最豐富的地區,但遠遠沒有得到充分利用。簡化的解釋指南開發40多年前被高估和低估的臨床受益(1、2、3),從而限製醫生的能力來衡量癌症治療工作。訓練在世界最大的專有數據庫癌症成像和縱向臨床背景下,公司的最先進的深度學習模型預測臨床端點幫助量化治療效果超出了簡單的和主觀的腫瘤大小的測量。資金將用於背板的發展規模,Altis”AI-powered成像生物標誌物的平台,在實體瘤類型和治療領域。領先的生物製藥公司拜耳製藥使用背板來分析成像1 - 3期臨床試驗的數據更有意義。“研發、成像是一個核心組件的我們所做的臨床試驗和當前方法不利用它的全部潛力,”卡Haefliger說,醫學博士Debiopharm轉化醫學主管和董事會在Altis觀察者。 “We believe that AI-powered tools, such as those developed by Altis, will become the new standard for measuring clinical benefit not just in clinical trials, but also in clinical care.” Altis hosts proprietary prognostic models in the Nota cloud platform for biopharma R&D teams to automatically analyze clinical trial imaging data. Model predictions allow researchers to more accurately stratify patients at baseline and measure treatment effect across subpopulations. These insights help sponsors generate higher quality evidence earlier in clinical development to increase success rates in late-stage trials and inform critical R&D decisions spanning go/no-go, trial design, reimbursement strategy, and revivals of shelved assets. “It’s clear that AI will have a significant impact across healthcare, but Altis is uniquely positioned to transform the economics of clinical development,” said Kenneth Chenault, Managing Partner at Benchstrength and Board Director at Altis. “The Altis team has curated an unparalleled clinical imaging database in terms of both depth and breadth, which they are translating into actionable clinical insight thanks to their AI models.” “This milestone for Altis is a testament to Canada’s leading role in both AI and clinical research” said Sally Daub, Co-Founder and Board Chair at Altis. “Our goal is to accelerate therapeutic development and improve the standard of care.” Altis’ imaging-based prognostication (IPRO) technology has been validated in collaboration with Canada’s leading cancer centers, with results published in the Journal of Clinical Oncology – Clinical Cancer Informatics [4] and presented at the American Society of Clinical Oncology [5, 6].